Jason Parish, who is a Buchanan shareholder and part of the firm’s litigation section, was recently quoted in S&P Global Market Intelligence about how the $572 million fine Johnson & Johnson was ordered to pay will affect similar opioid litigation against pharmaceutical companies. Click here to read the article.